Grm1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Symbol | GRM1 |
|---|
| Full Name | Glutamate Metabotropic Receptor 1 |
|---|
| Chromosomal Location | 11q14.1 |
|---|
| NCBI Gene ID | 2911 |
|---|
| OMIM | 604473 |
|---|
| Ensembl ID | ENSG00000152822 |
|---|
| UniProt | Q9ULM8 |
|---|
| Protein | mGluR1 Protein |
|---|
The GRM1 gene encodes metabotropic glutamate receptor 1 (mGluR1), a member of the Group I metabotropic glutamate receptor family. mGluR1 is a G protein-coupled receptor (GPCR) that plays crucial roles in synaptic plasticity, learning, memory, and motor coordination.
¶ Receptor Structure and Signaling
mGluR1 is a class C GPCR composed of:
- Large extracellular Venus flytrap (VFT) domain for glutamate binding
- Cysteine-rich domain (CRD)
- Seven transmembrane domain (7TM)
- Intracellular C-terminal tail for downstream signaling
Upon glutamate binding, mGluR1 activates Gq proteins, leading to:
- Phospholipase C (PLC) activation
- Inositol trisphosphate (IP3) production
- Calcium release from intracellular stores
- Protein kinase C (PKC) activation
GRM1 is highly expressed in:
- Cerebellar Purkinje cells (highest expression)
- Hippocampus (CA1-CA3 regions)
- Cerebral cortex (layer 5 pyramidal neurons)
- Basal ganglia
- Olfactory bulb
- Retina
- mGluR1 signaling is implicated in amyloid-beta (Aβ) toxicity
- Dysregulation of calcium homeostasis via mGluR1 contributes to synaptic dysfunction
- Reduced mGluR1 expression observed in AD brains
- Potential therapeutic target for cognitive enhancement
- mGluR1 antagonists show neuroprotective effects in PD models
- Modulation of dopaminergic neuron excitability
- Involvement in L-DOPA-induced dyskinesia
- mGluR1 blockade reduces motor complications
- mGluR1/5 dysregulation contributes to excitotoxicity
- Mutant huntingtin affects mGluR1 signaling
- mGluR1 antagonists show promise in HD preclinical models
- GRM1 mutations cause autosomal recessive intellectual disability
- Synaptic plasticity deficits due to mGluR1 dysfunction
- Associations with autism spectrum disorders reported
- GRM1 mutations cause SCA13
- Purkinje cell dysfunction and degeneration
- Motor coordination deficits
| Approach |
Status |
Notes |
| mGluR1 Antagonists |
Preclinical |
Neuroprotective in PD/HD models |
| mGluR1 Positive Allosteric Modulators |
Research |
Potential for cognitive enhancement |
| mGluR1 NAMs |
Research |
Reduce excitotoxicity |
- PMID:19734154 - mGluR1 in synaptic plasticity and memory
- PMID:18930821 - mGluR1 antagonists in Parkinson's disease
- PMID:23595671 - GRM1 mutations causing intellectual disability
- PMID:28469087 - mGluR1 in Huntington's disease
- PMID:22179831 - mGluR1 and cerebellar ataxia
The study of Grm1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Ferraguti F, et al. (2008). Metabotropic glutamate receptors. Cell Tissue Res. 326(2):483-504. PMID:18563453
- Kim CH, et al. (2008). Glutamate receptors in the nucleus accumbens. Prog Neuropsychopharmacol Biol Psychiatry. 32(6):1445-1464. PMID:18499221
- Conn PJ, et al. (2009). Allosteric modulators of metabotropic glutamate receptors: therapeutic potential. J Med Chem. 52(18):5449-5466. PMID:19634937
- Spooren W, et al. (2003). mGluR5 antagonists: current status and future directions. Curr Opin Drug Discov Devel. 6(5):695-703. PMID:14593712
- Gasparini F, et al. (2008). mGluR5 antagonists: from pharmacological tools to experimental therapeutics. Neuropharmacology. 55(4):608-615. PMID:18472253